Prospective safety and immunogenicity study of GV1001 (tertomotide), Granulocyte macrophage colony stimulating factor (GM-CSF) and gemcitabine administered to pancreatic cancer patients

Trial Profile

Prospective safety and immunogenicity study of GV1001 (tertomotide), Granulocyte macrophage colony stimulating factor (GM-CSF) and gemcitabine administered to pancreatic cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Tertomotide (Primary) ; Gemcitabine; Granulocyte macrophage colony stimulating factor
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top